# A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

> **NCT04996030** · PHASE1 · SUSPENDED · sponsor: **Syros Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Acute Promyelocytic Leukemia

## Interventions

- **DRUG:** SY-2101
- **DRUG:** Arsenic Trioxide

## Key facts

- **NCT ID:** NCT04996030
- **Lead sponsor:** Syros Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-09-17
- **Primary completion:** 2024-01-03
- **Final completion:** 2024-04
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Prioritization
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04996030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04996030, "A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04996030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*